Date: Anytime
Format: Full text
Viewing results
11 -
20 of
11
-
Annals of Oncology : Official Journal... Nov 2018
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.
PubMed: 29390097
DOI: 10.1093/annonc/mdx812